1. Market Research
  2. > Biotechnology Market Trends
  3. > Distribution Partnering Terms and Agreements in Pharma, Biotech and Diagnostics

The Distribution Partnering Terms and Agreements in Pharma, Biotech and Diagnostics report provides comprehensive understanding and unprecedented access to the distribution partnering agreements entered into by the worlds leading biopharma companies.

The report provides a detailed understand and analysis of how and why companies enter distribution deals.
The majority of deals are multicomponent whereby the licensor offers a right to distribute the resultant product of the research collaboration. There are also numerous pure distribution deals whereby the products originator takes on a distribution partner in order to maximize a products presence in the marketplace.

Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases and databases do not.

The initial chapters of this report provide an orientation of distribution dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an analysis of the trends in distribution as well as a discussion on the merits of the type of deal.

Chapter 3 provides an overview of the structure of distribution deals. The chapter includes numerous case studies to enable understanding of both pure distribution deals and multicomponent deals where distribution forms a part.

Chapter 4 provides a review of the leading distribution deals since 2009. Deals are listed by headline value, signed by big pharma and big biotech, most active bigpharma and bigbiotech, and most active of all biopharma companies. Where the deal has an agreement contract published at the SEC a link provides online access to the contract via the Current Agreements deals and alliances database.

Chapter 5 provides a comprehensive listing of the top 50 big pharma companies with a brief summary followed by a comprehensive listing of distribution deals available in the public domain. Where available, each deal title links via Current Agreements deals and alliances database to an online version of the actual contract document, providing easy access to each contract document on demand.

Chapter 6 provides a comprehensive listing of the top 50 big biotech companies with a brief summary followed by a comprehensive listing of distribution deals available in the public domain. Where available, each deal title links via Current Agreements deals and alliances database to an online version of the actual contract document, providing easy access to each contract document on demand.

Chapter 7 provides a comprehensive and detailed review of distribution deals organized by company A-Z, therapy, technology and industry type signed and announced since 2009 where a contract document is available. Contract documents provide an indepth insight into the actual deal terms agreed between the parties with respect to the distribution deal.

In addition the report includes a comprehensive listing of all distribution deals announced since 2009.
Each listing is organized as an appendix by company A-Z, stage of development at signing, therapeutic area and industry type. Each deal title links via hyperlink to an online version of the deal record including, where available, the actual contract document.

The report also includes numerous table and figures that illustrate the trends and activities in distribution dealmaking since 2009.

In conclusion, this report provides everything a prospective dealmaker needs to know about distribution alliances.

Report scope

Distribution Partnering Terms and Agreements is intended to provide the reader with an in-depth understanding of the distribution trends and structure of deals entered into by leading biopharma companies worldwide.

Distribution Partnering Terms and Agreements includes:

Trends in distribution dealmaking in the biopharma industry since 2009
Analysis of distribution deal structure
Case studies of real-life distribution deals
Access to over 2,500 distribution deals documents
The leading distribution deals by value since 2009
Most active distribution dealmakers since 2009
The leading distribution partnering resources

In Distribution Partnering Terms and Agreements, the available deals are listed by:

Company A-Z
Headline value
Stage of development at signing
Therapeutic area
Technology type

Each deal title links via Weblink to an online version of the actual deal record, providing easy access to each contract document where available.
The Distribution Partnering Terms and Agreements report provides comprehensive access to available records for over 2,500 distribution deals, including contract documents where available. Analyzing actual contract agreements allows assessment of the following:

What are the precise rights granted or optioned?
What is actually granted by the agreement to the partner company?
What exclusivity is granted?
What is the payment structure for the deal?
How aresalesand payments audited?
What is the deal term?
How are the key terms of the agreement defined?
How are IPRs handled and owned?
Who is responsible for commercialization?
Who is responsible for development, supply, and manufacture?
How is confidentiality and publication managed?
How are disputes to be resolved?
Under what conditions can the deal be terminated?
What happens when there is a change of ownership?
What sublicensing and subcontracting provisions have been agreed?
Which boilerplate clauses does the company insist upon?
Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
Which jurisdiction does the company insist upon for agreement law?

Table Of Contents

Distribution Partnering Terms and Agreements in Pharma, Biotech and Diagnostics
Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in distribution dealmaking

2.1. Introduction
2.2. Definition of distribution deals
2.3. Trends in distribution deals since 2009
2.3.1. Attributes of pure distribution deals
2.3.2. Attributes of distribution in multi-component deals
2.4 . Aligning partners to make the distribution agreement work

Chapter 3 - Overview of distribution deal structure

3.1. Introduction
3.2.Distribution agreement structure
3.3. Example distribution agreements
3.3.1. Case study 1: Zeltiq Aesthetics - Advance Medical - 18 March 2011
3.3.2. Case study 2: QLT - ASD Speciality Healthcare - January 2010
3.4 Distribution rights as part of a wider alliance agreement
3.4.1. Case study 1: Caleco Pharma - Natac Biotech - March 2010
3.4.2. Case study 2: Purdue Pharma - Transcept Pharmaceuticals - July 2009

Chapter 4 - Leading distribution deals

4.1. Introduction
4.2. Top distribution deals by value
4.3. Most active distribution dealmakers
4.4. Big pharma distribution deal activity
4.5. Big biotech distribution deal activity

Chapter 5 - Big pharma distribution deals

5.1. Introduction
5.2. How to use distribution deals
5.3. Big pharma distribution partnering company profiles

Chapter 6 - Big biotech distribution deals

6.1. Introduction
6.2. How to use big biotech partnering deals
6.3. Big biotech distribution partnering company profiles


Chapter 7 - Distribution deals including contracts directory

7.1. Introduction
7.2. Distribution deals with contracts by company A-Z
7.3. Distribution deals with contracts by therapeutic target
7.4 Distribution deals with contracts by technology type
7.5. Distribution deals with contracts by industry sector target

About Wildwood Ventures
Current Partnering
Current Agreements
Recent report titles from Current Partnering
Order Form - Upgrades to subscription access products
Order Form - Reports

See accompanying volume for the following appendices

Appendix 1 - Distribution dealmaking companies A-Z
Appendix 2 - By stage of development
Appendix 3 - By therapeutic target
Appendix 4 - By technology type
Appendix 5 - Distribution dealmaking references
Appendix 6 - Resources
Appendix 7 - Deal type definitions
Appendix 8 - Resources

TABLE OF FIGURES

Figure 1: Definition of distribution
Figure 2: Trends in distribution deal announcements, 2009-2014
Figure 3: Distribution deals signed at each phase of development, 2009-2014
Figure 4: Issues in implementing distribution agreements
Figure 5: Distribution agreements - what should a contract include?
Figure 6: Components of the distribution deal structure
Figure 7: Top distribution deals by value since 2009
Figure 8: Most active distribution dealmakers 2009-2014
Figure 9: Big pharma - top 50 - distribution deals 2009 to 2014
Figure 10: Big pharma distribution deal frequency - 2009 to 2014
Figure 11: Big biotech - distribution deals 2009 to 2014
Figure 12: Big biotech distribution deal frequency - 2009 to 2014

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Bioreactors Market by Scale Range, Material, Usage, Suppliers, End-User, Region - Global Forecast to 2021

Bioreactors Market by Scale Range, Material, Usage, Suppliers, End-User, Region - Global Forecast to 2021

  • $ 18000
  • Industry report
  • September 2016
  • by MarketsandMarkets

The global bioreactors market is expected to reach to USD 1,417 million by 2021 from USD 955 million in 2015, at a CAGR of 6.8% between 2015 and 2021.The increase in adoption of single-use technologies, ...

2016 Europe Cancer Diagnostics Market: Supplier Shares, Country Volume and Sales Segment Forecasts, Innovative Technologies, Competitive Strategies--France, Germany, Italy, Spain, UK

2016 Europe Cancer Diagnostics Market: Supplier Shares, Country Volume and Sales Segment Forecasts, Innovative Technologies, Competitive Strategies--France, Germany, Italy, Spain, UK

  • $ 12800
  • Industry report
  • September 2016
  • by Venture Planning Group

Complete report $19,700.  DataPack (test volumes, sales forecasts, supplier shares) $12,800. VPGMarketResearch’s new report is a study of the major business opportunities emerging in the European cance ...

Flat-Rate Access to R&D Database & Reports from La Merie Publishing

Flat-Rate Access to R&D Database & Reports from La Merie Publishing

  • $ 8470
  • Industry report
  • November 2016
  • by La Merie Publishing

Flat-Rate Access to R&D Database & Reports from La Merie Publishing - R&D Drug Pipeline Database: 1-Year Subscription - Flat-Rate Subscription to La Merie Publishing Reports & News Services A one-yea ...


ref:plp2015

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.